Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1529313

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1529313

Europe T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type, By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others), By Country and Growth Forecast, 2024 - 2031

PUBLISHED:
PAGES: 91 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Multi User License)
USD 1800
PDF (Corporate User License)
USD 2520

Add to Cart

The Europe T-cell Lymphoma Market would witness market growth of 8.2% CAGR during the forecast period (2024-2031).

The Germany market dominated the Europe T-cell Lymphoma Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $246.2 million by 2031. The UK market is exhibiting a CAGR of 7.2% during (2024 - 2031). Additionally, The France market would experience a CAGR of 9% during (2024 - 2031).

Treatment strategies for these lymphomas are tailored based on subtype, disease stage, patient characteristics, and response to initial therapy. Combination chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) are standard for many aggressive these lymphomas, varying depending on the subtype and clinical presentation. Novel agents targeting specific pathways in these lymphomas are under investigation, including histone deacetylase (HDAC) inhibitors (e.g., vorinostat), which are approved for cutaneous these lymphomas (CTCL) and are being studied in systemic diseases.

Immune checkpoint inhibitors (e.g., pembrolizumab) and monoclonal antibodies (e.g., alemtuzumab) are being explored for their efficacy in refractory or relapsed these lymphomas. These drugs leverage the immune system to target cancer cells. Autologous or allogeneic stem cell transplantation (ASCT) may be considered for eligible patients with high-risk or relapsed/refractory disease, aiming to achieve long-term remission and cure. Managing these lymphomas extends beyond initial treatment to long-term monitoring and supportive care. Regular monitoring with clinical evaluations, imaging studies, and laboratory tests helps assess treatment response, detect disease recurrence, and manage treatment-related complications.

Governments and regulatory bodies in Europe respond to the growing cancer burden by implementing policies and regulations that support cancer prevention, early detection, and treatment. This includes funding research initiatives, establishing national cancer control programs, and ensuring equitable access to cancer care services for patients with these lymphomas. The increasing prevalence of cancer in Europe underscores the importance of patient support services and survivorship programs tailored to the needs of individuals with these lymphomas. These initiatives provide psychosocial support, educational resources, and rehabilitation services to enhance quality of life during and after treatment. Therefore, the high rates of cancer cases in the region is driving the growth of the market.

Based on Type, the market is segmented into Peripheral (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, and Others) and Lymphoblastic. Based on Therapy, the market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled

  • Bristol Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd
  • Acrotech Biopharma Inc. (Aurobindo Pharma USA)
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Citius Pharmaceuticals, Inc.
  • Genor Biopharma Co. Ltd.
  • Innate Pharma SA
  • Dizal Pharmaceutical Co. Ltd.

Europe T-cell Lymphoma Market Report Segmentation

By Type

  • Peripheral
    • Cutaneous T-cell Lymphoma
    • Anaplastic Large Cell Lymphoma
    • Angio-immuno-blastic T-cell Lymphoma
    • Others
  • Lymphoblastic

By Therapy

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Europe T-cell Lymphoma Market, by Type
    • 1.4.2 Europe T-cell Lymphoma Market, by Therapy
    • 1.4.3 Europe T-cell Lymphoma Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market at a Glance

  • 2.1 Key Highlights

Chapter 3. Market Overview

  • 3.1 Introduction
    • 3.1.1 Overview
      • 3.1.1.1 Market Composition and Scenario
  • 3.2 Key Factors Impacting the Market
    • 3.2.1 Market Drivers
    • 3.2.2 Market Restraints
    • 3.2.3 Market Opportunities
    • 3.2.4 Market Challenges
  • 3.3 Porter Five Forces Analysis

Chapter 4. Europe T-cell Lymphoma Market by Type

  • 4.1 Europe Peripheral Market by Country
  • 4.2 Europe T-cell Lymphoma Market by Peripheral Type
    • 4.2.1 Europe Cutaneous T-cell Lymphoma Market by Country
    • 4.2.2 Europe Anaplastic Large Cell Lymphoma Market by Country
    • 4.2.3 Europe Angio-immuno-blastic T-cell Lymphoma Market by Country
    • 4.2.4 Europe Others Market by Country
  • 4.3 Europe Lymphoblastic Market by Country

Chapter 5. Europe T-cell Lymphoma Market by Therapy

  • 5.1 Europe Chemotherapy Market by Country
  • 5.2 Europe Radiotherapy Market by Country
  • 5.3 Europe Immunotherapy Market by Country
  • 5.4 Europe Stem Cell Transplantation Market by Country
  • 5.5 Europe Others Market by Country

Chapter 6. Europe T-cell Lymphoma Market by Country

  • 6.1 Germany T-cell Lymphoma Market
    • 6.1.1 Germany T-cell Lymphoma Market by Type
      • 6.1.1.1 Germany T-cell Lymphoma Market by Peripheral Type
    • 6.1.2 Germany T-cell Lymphoma Market by Therapy
  • 6.2 UK T-cell Lymphoma Market
    • 6.2.1 UK T-cell Lymphoma Market by Type
      • 6.2.1.1 UK T-cell Lymphoma Market by Peripheral Type
    • 6.2.2 UK T-cell Lymphoma Market by Therapy
  • 6.3 France T-cell Lymphoma Market
    • 6.3.1 France T-cell Lymphoma Market by Type
      • 6.3.1.1 France T-cell Lymphoma Market by Peripheral Type
    • 6.3.2 France T-cell Lymphoma Market by Therapy
  • 6.4 Russia T-cell Lymphoma Market
    • 6.4.1 Russia T-cell Lymphoma Market by Type
      • 6.4.1.1 Russia T-cell Lymphoma Market by Peripheral Type
    • 6.4.2 Russia T-cell Lymphoma Market by Therapy
  • 6.5 Spain T-cell Lymphoma Market
    • 6.5.1 Spain T-cell Lymphoma Market by Type
      • 6.5.1.1 Spain T-cell Lymphoma Market by Peripheral Type
    • 6.5.2 Spain T-cell Lymphoma Market by Therapy
  • 6.6 Italy T-cell Lymphoma Market
    • 6.6.1 Italy T-cell Lymphoma Market by Type
      • 6.6.1.1 Italy T-cell Lymphoma Market by Peripheral Type
    • 6.6.2 Italy T-cell Lymphoma Market by Therapy
  • 6.7 Rest of Europe T-cell Lymphoma Market
    • 6.7.1 Rest of Europe T-cell Lymphoma Market by Type
      • 6.7.1.1 Rest of Europe T-cell Lymphoma Market by Peripheral Type
    • 6.7.2 Rest of Europe T-cell Lymphoma Market by Therapy

Chapter 7. Company Profiles

  • 7.1 Bristol Myers Squibb Company
    • 7.1.1 Company Overview
    • 7.1.2 SWOT Analysis
  • 7.2 Daiichi Sankyo Company, Limited
    • 7.2.1 Company Overview
    • 7.2.2 SWOT Analysis
  • 7.3 Eisai Co., Ltd.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expenses
    • 7.3.5 SWOT Analysis
  • 7.4 Acrotech Biopharma Inc. (Aurobindo Pharma USA)
    • 7.4.1 Company Overview
  • 7.5 Shenzhen Chipscreen Biosciences Co., Ltd.
    • 7.5.1 Company Overview
  • 7.6 Citius Pharmaceuticals, Inc.
    • 7.6.1 Company Overview
    • 7.6.2 Recent strategies and developments:
      • 7.6.2.1 Trials and Approvals:
  • 7.7 Genor Biopharma Co. Ltd
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Research & Development Expenses
  • 7.8 Innate Pharma SA
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Research & Development Expenses
  • 7.9 Dizal Pharmaceutical Co. Ltd.
    • 7.9.1 Company Overview
    • 7.9.2 Recent strategies and developments:
      • 7.9.2.1 Trials and Approvals:

LIST OF TABLES

  • TABLE 1 Europe T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 2 Europe T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 3 Europe T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 4 Europe T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 5 Europe Peripheral Market by Country, 2020 - 2023, USD Million
  • TABLE 6 Europe Peripheral Market by Country, 2024 - 2031, USD Million
  • TABLE 7 Europe T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 8 Europe T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 9 Europe Cutaneous T-cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 10 Europe Cutaneous T-cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 11 Europe Anaplastic Large Cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 12 Europe Anaplastic Large Cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 13 Europe Angio-immuno-blastic T-cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 14 Europe Angio-immuno-blastic T-cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 15 Europe Others Market by Country, 2020 - 2023, USD Million
  • TABLE 16 Europe Others Market by Country, 2024 - 2031, USD Million
  • TABLE 17 Europe Lymphoblastic Market by Country, 2020 - 2023, USD Million
  • TABLE 18 Europe Lymphoblastic Market by Country, 2024 - 2031, USD Million
  • TABLE 19 Europe T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 20 Europe T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 21 Europe Chemotherapy Market by Country, 2020 - 2023, USD Million
  • TABLE 22 Europe Chemotherapy Market by Country, 2024 - 2031, USD Million
  • TABLE 23 Europe Radiotherapy Market by Country, 2020 - 2023, USD Million
  • TABLE 24 Europe Radiotherapy Market by Country, 2024 - 2031, USD Million
  • TABLE 25 Europe Immunotherapy Market by Country, 2020 - 2023, USD Million
  • TABLE 26 Europe Immunotherapy Market by Country, 2024 - 2031, USD Million
  • TABLE 27 Europe Stem Cell Transplantation Market by Country, 2020 - 2023, USD Million
  • TABLE 28 Europe Stem Cell Transplantation Market by Country, 2024 - 2031, USD Million
  • TABLE 29 Europe Others Market by Country, 2020 - 2023, USD Million
  • TABLE 30 Europe Others Market by Country, 2024 - 2031, USD Million
  • TABLE 31 Europe T-cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 32 Europe T-cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 33 Germany T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 34 Germany T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 35 Germany T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 36 Germany T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 37 Germany T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 38 Germany T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 39 Germany T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 40 Germany T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 41 UK T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 42 UK T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 43 UK T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 44 UK T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 45 UK T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 46 UK T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 47 UK T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 48 UK T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 49 France T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 50 France T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 51 France T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 52 France T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 53 France T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 54 France T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 55 France T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 56 France T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 57 Russia T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 58 Russia T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 59 Russia T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 60 Russia T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 61 Russia T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 62 Russia T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 63 Russia T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 64 Russia T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 65 Spain T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 66 Spain T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 67 Spain T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 68 Spain T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 69 Spain T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 70 Spain T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 71 Spain T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 72 Spain T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 73 Italy T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 74 Italy T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 75 Italy T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 76 Italy T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 77 Italy T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 78 Italy T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 79 Italy T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 80 Italy T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 81 Rest of Europe T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 82 Rest of Europe T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 83 Rest of Europe T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 84 Rest of Europe T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 85 Rest of Europe T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 86 Rest of Europe T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 87 Rest of Europe T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 88 Rest of Europe T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 89 Key Information - Bristol Myers Squibb Company
  • TABLE 90 Key Information - Daiichi Sankyo Company, Limited
  • TABLE 91 Key Information - Eisai Co., Ltd.
  • TABLE 92 Key Information - Acrotech Biopharma Inc.
  • TABLE 93 Key Information - Shenzhen Chipscreen Biosciences Co., Ltd.
  • TABLE 94 Key Information - Citius Pharmaceuticals, Inc.
  • TABLE 95 Key Information - Genor Biopharma Co. Ltd
  • TABLE 96 Key Information - Innate Pharma SA
  • TABLE 97 Key Information - Dizal Pharmaceutical Co. Ltd.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!